reset
Close search icon

Leaf Expression Systems launch SupraVec, the next generation in plant-based expression technology

07 September 2021

News main image

Leaf Expression Systems (Leaf), a biotechnology company based on Norwich Research Park specialising in plant-based expression, today announced the launch of SupraVec, Leaf’s new proprietary vector-based expression technology for the rapid production of proteins, vaccines and complex biomolecules within the leaf tissue of plants.

SupraVec is a plant transient expression system designed with novel expression components to optimise yields. The expression technology delivers a three-fold improvement in the yield compared to Leaf’s previous pEAQ-HT system, also known as Hypertrans. The increased yield achieved by SupraVec will enable viable expression of a larger number of products and reduce the cost of goods for Leaf’s clients.

Simon Saxby, CEO: “The launch of SupraVec, our new proprietary expression technology, is a significant milestone for Leaf and greatly enhances the options we can offer our clients for expression and scale-up manufacture of their biologics. SupraVec is the result of excellent work by the Leaf team, led by Dr Nick Holton and Dr Albor Dobon-Alonso, and I am delighted that their efforts have led to this impressive and valuable achievement.”

Nick Holton, Principal Scientist – R&D “We are striving to obtain the highest possible protein yields, and the development of the SupraVec technology greatly enhances the level of protein that we can obtain during plant transient expression. This technology is a significant leap forward and will improve protein yields and the economics of plant transient expression.”

Share: Facebook Twitter

Related News

News main image

20 January 2022

New legislation will help farmers to grow more resistant, nutritious and productive crops in the UK

Read more
News main image

19 January 2022

Saving Species through genomics in megadiverse Colombia

Read more
Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
If you’re enjoying this article, sign up to our newsletter
Lorem ipsum dolor Lorem ipsum dolor Lorem ipsum dolor Lorem ipsum dolor Lorem ipsum dolor
ErrorHere